AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20716665 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic
Number of subjects: 63
Study 20716665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16962799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 46
Study 16962799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16294072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning (N = 21, kept prone for at least 8 hours and a maximum of 23 hours per day)
Number of subjects: 40
Study 16294072 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning (N = 19, positioned according to standard care guidelines)
Number of subjects: 40
Study 16294072 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 40
Study 16294072 — intervention group
Group type: COMPARATOR
Intervention: Supine positioning
Number of subjects: 40
Study 12173675 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched intervention
Number of subjects: 196
Study 12173675 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care intervention
Number of subjects: 196
Study 12173675 — intervention group
Group type: COMPARATOR
Intervention: Mismatched intervention
Number of subjects: 196
Study 12173675 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 196
Study 9803707 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 24
Study 9803707 — intervention group
Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 24
Study 7986667 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg amlodipine racemate
Number of subjects: 18
Study 2663318 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg ibuprofen
Number of subjects: 127
Study 2663318 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibuprofen
Number of subjects: 127
Study 2663318 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg acetaminophen
Number of subjects: 127
Study 2663318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 29659413 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application for AED delivery
Number of subjects: 61
Study 29659413 — intervention group
Group type: COMPARATOR
Intervention: Control group (no application)
Number of subjects: 61
Study 28398950 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester drink
Number of subjects: 12
Study 28398950 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 12
Study 26414724 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental matrix‐derived mesenchymal stem cells (PM‐MSCs) injection
Number of subjects: 5
Study 23128664 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 179
Study 23128664 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 179
Study 21996194 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 10
Study 21996194 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 18510173 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Genetaxyl at doses of 60 mg/m2, 120 mg/m2, and 180 mg/m2 with 10 mg/kg of oral cyclosporin A
Number of subjects: 9
Study 18510173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Genetaxyl (175 mg/m2, 3-h infusion)
Number of subjects: 9
Study 18510173 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Genaxyl (175 mg/m2, 3-h infusion)
Number of subjects: 9
Study 18510173 — intervention group
Group type: COMPARATOR
Intervention: Generic i.v. paclitaxel (Genaxol, containing 50% CrEL; 175 mg/m2, 3-h infusion)
Number of subjects: 9
Study 16585987 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice daily topical 1% pimecrolimus cream
Number of subjects: 26
Study 16585987 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly narrowband UVB
Number of subjects: 26
Study 16585987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (pimecrolimus + narrowband UVB)
Number of subjects: 26
Study 16585987 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 26
Study 15310050 — intervention group
Group type: EXPERIMENTAL
Intervention: Three levels of critical incident stress intervention
Number of subjects: 18
Study 10926647 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 0.25LT
Number of subjects: 10
Study 10926647 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 0.75LT
Number of subjects: 10
Study 10926647 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at LT
Number of subjects: 10
Study 10926647 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 1.25LT
Number of subjects: 10
Study 10926647 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at 1.75LT
Number of subjects: 10
Study 10926647 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at all intensities
Number of subjects: 10
Study 8816024 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrapubic (IP) surgical approach
Number of subjects: 86
Study 8816024 — intervention group
Group type: EXPERIMENTAL
Intervention: Penoscrotal (PS) surgical approach
Number of subjects: 86
Study 1586878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline chloride (5 micrograms or 50 micrograms)
Number of subjects: 12
Study 1586878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3514486 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoprofen
Number of subjects: 24
Study 3514486 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 24
Study 29644957 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 16
Study 29644957 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes (CD) diet
Number of subjects: 16
Study 27833917 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-step etch-and-rinse (Group 1)
Number of subjects: 32
Study 27833917 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step etch-and-rinse (Group 2)
Number of subjects: 32
Study 27833917 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etch (Group 3)
Number of subjects: 32
Study 27833917 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etch (Group 4)
Number of subjects: 32
Study 26037006 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based application and brochure (N=22)
Number of subjects: 45
Study 26037006 — intervention group
Group type: COMPARATOR
Intervention: Brochure only (N=23)
Number of subjects: 45
Study 22540895 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (invited for total PSA testing every second year)
Number of subjects: 2353
Study 22540895 — intervention group
Group type: COMPARATOR
Intervention: Control group (not invited for screening)
Number of subjects: 2353
Study 19837746 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR retainers (500 unidirectional glass fibres)
Number of subjects: 184
Study 19837746 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR retainers (1000 unidirectional glass fibres)
Number of subjects: 184
Study 19837746 — intervention group
Group type: COMPARATOR
Intervention: Multistranded bonded retainers (gold standard)
Number of subjects: 184
Study 19837746 — intervention group
Group type: COMPARATOR
Intervention: Control group (no retainers)
Number of subjects: 184
Study 18593778 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline
Number of subjects: 20
Study 18593778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16025784 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 16025784 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (sleep hygiene)
Number of subjects: 30
Study 11812555 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic nCPAP
Number of subjects: 118
Study 11812555 — intervention group
Group type: COMPARATOR
Intervention: Subtherapeutic nCPAP
Number of subjects: 118
Study 11812555 — intervention group
Group type: COMPARATOR
Intervention: Difference between Therapeutic and Subtherapeutic nCPAP
Number of subjects: 118
Study 10524888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandloop
Number of subjects: 53
Study 10524888 — intervention group
Group type: COMPARATOR
Intervention: Standard loop
Number of subjects: 53
Study 7734256 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous systemic i.v. butorphanol infusion (83.3 micrograms h‐1)
Number of subjects: 22
Study 7734256 — intervention group
Group type: COMPARATOR
Intervention: Continuous brachial plexus infusion of butorphanol (83.3 micrograms h‐1)
Number of subjects: 22
Study 1838818 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 20
Study 1838818 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 6106785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen supplements
Number of subjects: 37
Study 6106785 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 37
Study 6106785 — intervention group
Group type: EXPERIMENTAL
Intervention: Defaulted from oestrogen therapy
Number of subjects: 37
Study 6106785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen dosage
Number of subjects: 37
Study 29853651 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐P3BZA
Number of subjects: 11
Study 29853651 — intervention group
Group type: COMPARATOR
Intervention: 18F‐FDG
Number of subjects: 11
Study 28114795 — intervention group
Group type: EXPERIMENTAL
Intervention: APT198K (xyloglucan plus heat‐killed Lactobacillus reuteri SGL01 and Bifidobacterium brevis SGB01)
Number of subjects: 46
Study 28114795 — intervention group
Group type: COMPARATOR
Intervention: Lactase dietary supplement
Number of subjects: 46
Study 25733467 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified maize (34 μg zinc/g grain)
Number of subjects: 60
Study 25733467 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified maize (60 μg zinc/g)
Number of subjects: 60
Study 25733467 — intervention group
Group type: COMPARATOR
Intervention: Control maize (21 μg zinc/g)
Number of subjects: 60
Study 23950967 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention (educational intervention)
Number of subjects: 179
Study 23950967 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 179
Study 21386767 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-gauge PPV with Densiron-68 and 360° endolaser
Number of subjects: 82
Study 21386767 — intervention group
Group type: COMPARATOR
Intervention: 20-gauge PPV with encircling scleral buckling and SF6
Number of subjects: 82
Study 19647311 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention (writing about personal emotional events related to peer problems)
Number of subjects: 153
Study 19647311 — intervention group
Group type: COMPARATOR
Intervention: Trivial topics (control group)
Number of subjects: 153
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict metabolic control
Number of subjects: 0
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight blood pressure control
Number of subjects: 0
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation
Number of subjects: 0
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy
Number of subjects: 0
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein kinase C inhibitors
Number of subjects: 0
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal steroid injections
Number of subjects: 0
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-vascular endothelial growth factor agents
Number of subjects: 0
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors
Number of subjects: 0
Study 17277392 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone inhibitors
Number of subjects: 0
Study 17277392 — intervention group
Group type: COMPARATOR
Intervention: Anti-platelet agents
Number of subjects: 0
Study 17277392 — intervention group
Group type: COMPARATOR
Intervention: Aldose reductase inhibitors
Number of subjects: 0
Study 17277392 — intervention group
Group type: COMPARATOR
Intervention: Advanced glycation end-products inhibitors
Number of subjects: 0
Study 14717743 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained subjects (T)
Number of subjects: 23
Study 14717743 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtrained athletes (OA)
Number of subjects: 23
Study 14717743 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 23
Study 11154393 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy training for nurses
Number of subjects: 150
Study 11154393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 150
Study 9363516 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity intervention town
Number of subjects: 1620
Study 9363516 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity intervention town
Number of subjects: 1620
Study 9363516 — intervention group
Group type: COMPARATOR
Intervention: Control town
Number of subjects: 1620
Study 9363516 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study area
Number of subjects: 1620
Study 8239106 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulization of 30 mg albuterol over 110 minutes
Number of subjects: 0
Study 8239106 — intervention group
Group type: COMPARATOR
Intervention: Intermittent nebulization of 30 mg albuterol over 110 minutes
Number of subjects: 0
Study 8239106 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Continuous and Intermittent nebulization)
Number of subjects: 0
Study 3116985 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 50 mg b.i.d. for 3 weeks
Number of subjects: 40
Study 3116985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28866297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 146
Study 28866297 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 146
Study 26818630 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist for handover
Number of subjects: 121
Study 26818630 — intervention group
Group type: COMPARATOR
Intervention: Nonstandardized handover procedure (Control)
Number of subjects: 121
Study 25511814 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1,200 mg/day)
Number of subjects: 670
Study 25511814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 670
Study 22076415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 47
Study 22076415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19887830 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis in patients with diabetic nephropathy (DN)
Number of subjects: 126
Study 19887830 — intervention group
Group type: COMPARATOR
Intervention: Hemodialysis in patients with diabetic renal vasculopathy (DV)
Number of subjects: 126
Study 19887830 — intervention group
Group type: COMPARATOR
Intervention: Comparison of vascular disease prevalence
Number of subjects: 126
Study 18440398 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education programmes (PEP)
Number of subjects: 170
Study 16319148 — intervention group
Group type: EXPERIMENTAL
Intervention: Tris-acryl gelatin microspheres (TAGM)
Number of subjects: 36
Study 16319148 — intervention group
Group type: COMPARATOR
Intervention: Spherical polyvinyl alcohol (PVA)
Number of subjects: 36
Study 12614743 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐dose intravenous methylprednisolone pulse therapy (1 g per day for 3 successive days, repeated 3 times within 3 weeks) followed by 24‐Gy orbital radiotherapy
Number of subjects: 39
Study 12614743 — intervention group
Group type: COMPARATOR
Intervention: High‐dose intravenous methylprednisolone pulse therapy without orbital radiotherapy
Number of subjects: 39
Study 10702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol with aspirin
Number of subjects: 12
Study 10702891 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol alone
Number of subjects: 12
Study 8951195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (2 g)
Number of subjects: 20
Study 8951195 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 1663163 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (10‐40 mg)
Number of subjects: 169
Study 1663163 — intervention group
Group type: COMPARATOR
Intervention: enalapril (5‐20 mg)
Number of subjects: 169
Study 7160424 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablets (1200 mg)
Number of subjects: 0
Study 7160424 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated tablets (650 mg)
Number of subjects: 0
Study 7160424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium salicylate (1.0 g)
Number of subjects: 0
Study 31914878 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation for nocturnal hypertension
Number of subjects: 2511
Study 31914878 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive equation for nondipping SBP
Number of subjects: 2511
Study 31399147 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT039-releasing transdermal patch
Number of subjects: 44
Study 31399147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study 28130749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (IA) + methylprednisolone
Number of subjects: 0
Study 28130749 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (IA) + IVIG
Number of subjects: 0
Study 28130749 — intervention group
Group type: COMPARATOR
Intervention: Intravenous azithromycin (IA) + methylprednisolone (group C1)
Number of subjects: 0
Study 28130749 — intervention group
Group type: COMPARATOR
Intervention: Intravenous azithromycin (IA) + IVIG (group C2)
Number of subjects: 0
Study 28130749 — intervention group
Group type: COMPARATOR
Intervention: Intravenous azithromycin (IA) alone (group C)
Number of subjects: 0
Study 24861845 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal bacterial colonization (specifically Pr. intermedia)
Number of subjects: 26
Study 24861845 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bacterial counts
Number of subjects: 26
Study 24822268 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg)
Number of subjects: 50
Study 24822268 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (50 mg) and low-dose prednisolone (5 mg)
Number of subjects: 50
Study 24822268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21728748 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy for 6 months
Number of subjects: 40
Study 21728748 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 21728748 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint therapy
Number of subjects: 40
Study 19204514 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoreduced blood transfusions
Number of subjects: 268
Study 19204514 — intervention group
Group type: COMPARATOR
Intervention: Regular blood transfusions
Number of subjects: 268
Study 18088218 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Training + Classroom Intervention (PT + CR)
Number of subjects: 0
Study 18088218 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom Intervention (CR)
Number of subjects: 0
Study 18088218 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0
Study 15220255 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 3933
Study 15220255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3933
Study 11439206 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (ART) - 1.8 Gy twice a day to a dose of 59.4 Gy in 33 fractions over 24 days
Number of subjects: 350
Study 11439206 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT) - 2 Gy/day to a dose of 70 Gy in 35 fractions over 49 days
Number of subjects: 350
Study 11439206 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated radiotherapy (ART)
Number of subjects: 350
Study 11439206 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (CRT)
Number of subjects: 350
Study 9731172 — intervention group
Group type: EXPERIMENTAL
Intervention: Planetree Model Hospital Unit
Number of subjects: 0
Study 7973469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive retraining intervention (15 hours of repeated practice with computer-mediated vigilance tasks)
Number of subjects: 33
Study 7973469 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 33
Study 2500497 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Number of subjects: 19
Study 2500497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 773801 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (100 mg i.m. twice daily for 12 days, then 50 mg orally three times daily for 48 days)
Number of subjects: 64
Study 773801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28606000 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavior therapy
Number of subjects: 64
Study 28606000 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy
Number of subjects: 64
Study 28606000 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 64
Study 27558585 — intervention group
Group type: EXPERIMENTAL
Intervention: Meratrim (400 mg twice daily)
Number of subjects: 60
Study 27558585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24965754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral nerve stimulation (SNS) ON
Number of subjects: 20
Study 24965754 — intervention group
Group type: COMPARATOR
Intervention: Sacral nerve stimulation (SNS) OFF
Number of subjects: 20